TVTX Latest Headlines

Travere Therapeutics: Buy Rating Reiterated on FILSPARI Progress, Pipeline Strength, and Unchanged $67 Price Target

at www.tipranks.com (Mon, 22-Jun 6:55 AM)

Travere’s $475 Million Convertible Notes Offering Signals Strategic Shift with 2032 Maturity and Repurchase Plan

Market Chameleon (Thu, 7-May 9:46 AM)

TVTX Rallies after FDA Grants Full Approval to FILSPARI, Expanding Treatment for Rare Kidney Disease

Market Chameleon (Tue, 14-Apr 10:29 AM)

FDA Approves FILSPARI for FSGS: Travere Therapeutics Achieves a First for Rare Kidney Disease

Market Chameleon (Tue, 14-Apr 7:29 AM)